<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431391</url>
  </required_header>
  <id_info>
    <org_study_id>P10-2</org_study_id>
    <nct_id>NCT01431391</nct_id>
  </id_info>
  <brief_title>Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer</brief_title>
  <official_title>A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dendreon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dendreon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether ADT started before or after
      sipuleucel-T leads to a better immune system response. This study will also evaluate the
      safety of sipuleucel-T treatment, immune system responses over time, the characteristics of
      sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure change in immune response to PA2024 by IFN-gamma production ELISPOT following sipuleucel-T/ADT treatment regimens.</measure>
    <time_frame>Change in immune response from baseline through Month 24</time_frame>
    <description>To determine whether ADT started before or after sipuleucel-T leads to superior augmentation of immune response to sipuleucel-T.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>From baseline up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in immune responses over time</measure>
    <time_frame>From baseline through Month 24</time_frame>
    <description>Immune responses will be assessed from baseline through Month 24 by IFN-gamma ELISPOT assay, T cell proliferation assay, and production of antibodies (humoral response) to PAP and/or PA2024.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in sipuleucel-T product parameters: CD54 upregulation, number of CD54+ cells, and total nucleated cell number</measure>
    <time_frame>Over the course of sipuleucel-T therapy (approximately 1 month)</time_frame>
    <description>A course of sipuleucel-T therapy consists of 3 complete doses given at approximately 2-week intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in PSA over time</measure>
    <time_frame>From baseline through Month 27</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: sipuleucel-T followed by ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 2 weeks following the last sipuleucel-T infusion, subjects will receive one leuprolide acetate depot injection followed by a second injection 6 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: ADT followed by sipuleucel-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 12 weeks prior to the first sipuleucel-T infusion, subjects will receive one leuprolide acetate depot injection followed by a second injection 6 months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sipuleucel-T</intervention_name>
    <description>Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).</description>
    <arm_group_label>Arm 1: sipuleucel-T followed by ADT</arm_group_label>
    <arm_group_label>Arm 2: ADT followed by sipuleucel-T</arm_group_label>
    <other_name>PROVENGE(R)</other_name>
    <other_name>APC8015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <description>45.0 mg depot injection, 2 doses 6 months apart</description>
    <arm_group_label>Arm 1: sipuleucel-T followed by ADT</arm_group_label>
    <arm_group_label>Arm 2: ADT followed by sipuleucel-T</arm_group_label>
    <other_name>Eligard(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented prostate cancer

          -  Prior primary therapy for prostate cancer

          -  Rising prostate specific antigen (PSA) with a PSA doubling time (PSADT) of ≤ 12
             months

          -  Non-metastatic disease with ECOG performance status ≤ 1

          -  Testosterone ≥ 200 ng/dL ≤ 28 days of registration

          -  Adequate hematologic, renal, and liver function

          -  Must live in a permanent residence within a comfortable driving distance (roundtrip
             within one day) to the clinical research site

        Exclusion Criteria:

          -  Requires systemic ongoing immunosuppressive therapy

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to sipuleucel-T or GM-CSF

          -  Prior sipuleucel-T therapy

          -  Prior ADT therapy ≤ 6 months prior to registration or more than 6 months duration in
             total

          -  Disease-free and off treatment for 10 years for other stage III/IV malignancies or 5
             years for other stage I/II malignancies

          -  Prior experimental immunotherapy within 1 year

          -  Received denosumab or XRT ≤ 6 months prior to registration

          -  Received chemotherapy or GM-CSF ≤ 90 days prior to registration

          -  Received any of the following medications or interventions ≤ 28 days prior to
             registration

               -  major surgery requiring general anesthesia

               -  systemic immunosuppressive therapy

               -  other prescription treatment for prostate cancer

          -  Active infection within 1 week of registration

          -  Likely to receive XRT or surgery for prostate cancer during the study period
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candice McCoy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dendreon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Center of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego / Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>91914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC + USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYOH Albany Cancer Center at Patroon Creek</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Care Physicians, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Strand Urology</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 11, 2015</lastchanged_date>
  <firstreceived_date>August 5, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune therapy</keyword>
  <keyword>cancer vaccine</keyword>
  <keyword>therapeutic vaccine</keyword>
  <keyword>therapeutic cancer vaccine</keyword>
  <keyword>vaccine</keyword>
  <keyword>dendritic cells</keyword>
  <keyword>PSA</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Genital Neoplasms, Male</keyword>
  <keyword>Urogenital Neoplasms</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Prostatic Diseases</keyword>
  <keyword>Androgens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>immunology</keyword>
  <keyword>hormone therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>LHRH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
